Last reviewed · How we verify
NCT06269978
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Phase 1 trial testing Biopsy in Metastatic Colorectal Carcinoma in 24 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Arjun Mittra |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 31 December 2024 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Biopsy
- Biospecimen Collection — full drug profile →
- Computed Tomography
- Diagnostic Laparoscopy
- Fluorouracil — full drug profile →
- Magnetic Resonance Imaging
- Oxaliplatin (Oxaliplatin) — full drug profile →
- Surgical Procedure
Conditions studied
- Metastatic Colorectal Carcinoma — all drugs for Metastatic Colorectal Carcinoma →
- Metastatic Malignant Neoplasm in the Peritoneum — all drugs for Metastatic Malignant Neoplasm in the Peritoneum →
- Stage IV Colorectal Cancer AJCC v8 — all drugs for Stage IV Colorectal Cancer AJCC v8 →
Sponsor
Arjun Mittra
Who can join
18 and older, any sex, with Metastatic Colorectal Carcinoma or Metastatic Malignant Neoplasm in the Peritoneum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Fluorouracil stops cells from making DNA and it may kill cancer cells. Both oxaliplatin and fluorouracil are approved by the Food and Drug Administration to treat patients with colorectal cancer, however administration of these drugs directly into the area between the muscles and organs in the abdomen (intraperitoneal) for the treatment of peritoneal metastases is experimental. Giving oxaliplatin and fluorouracil directly into the peritoneal space may be a safe and effective way of treating patients with peritoneal metastases from colorectal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06269978
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biopsy
Trials testing the same drug.
- NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym · Phase 1 · recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT06860815 — Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br · Phase 2 · recruiting
- NCT05741164 — Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory · Phase 2 · not yet recruiting
Other recruiting trials for Metastatic Colorectal Carcinoma
Currently open trials in the same condition.
- NCT06147037 — A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours · Phase 1 · recruiting
- NCT06265285 — Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an · Phase 2 · recruiting
- NCT05803382 — Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastati · Phase 1 · recruiting
- NCT05863195 — Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Pa · Phase 3 · recruiting
- NCT05733000 — CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06269978 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arjun Mittra
- Last refreshed: 10 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06269978.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing